<p>蘇黎世州立銀行在其最近向證券交易委員會提交的文件中表示，在第三季度將其在 Dynavax Technologies Co.（納斯達克代碼：DVAX - 免費報告）的股份減少了 78.1%。該基金在此期間出售了 92,157 股後，持有 25,880 股該生物製藥公司的股票。根據其最近向證券交易委員會提交的文件，蘇黎世州立銀行在 Dynavax Technologies 的持股價值為 288,000 美元。</p>
<p>獲取 <strong>Dynavax Technologies</strong> 警報：</p>
<p>其他一些對沖基金和機構投資者最近也買賣了該股票的股份。Renaissance Technologies LLC 在第二季度將其在 Dynavax Technologies 的股份增加了 2.2%。Renaissance Technologies LLC 現在擁有 2,478,178 股該生物製藥公司的股票，價值 27,830,000 美元，此前在上個季度又購買了 53,600 股。Great Point Partners LLC 在第二季度將其在 Dynavax Technologies 的持倉增加了 87.7%。Great Point Partners LLC 現在擁有 2,374,000 股該生物製藥公司的股票，價值 26,660,000 美元，此前在上個季度又購買了 1,109,080 股。Millennium Management LLC 在第二季度購買了 Dynavax Technologies 的新股份，估值為 17,615,000 美元。Mizuho Markets Americas LLC 在第三季度將其在 Dynavax Technologies 的股份增加了 17.4%。Mizuho Markets Americas LLC 現在擁有 1,379,582 股該生物製藥公司的股票，價值 15,369,000 美元，此前在上個季度又收購了 204,475 股。最後，加拿大蒙特利爾銀行在第三季度將其在 Dynavax Technologies 的持股增加了 8.3%。加拿大蒙特利爾銀行現在擁有 1,077,081 股該生物製藥公司的股票，價值 11,848,000 美元，此前在此期間又收購了 82,449 股。96.96% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Dynavax Technologies 價格表現</h2>
<p>Dynavax Technologies 的股票在週一開盤價為 12.85 美元。該公司的速動比率為 12.34，流動比率為 13.23，債務與股本比率為 0.33。Dynavax Technologies Co.的 52 周最低價為 9.74 美元，52 周最高價為 15.01 美元。該公司的市值為 16.9 億美元，市盈率為 98.85，貝塔值為 1.33。該公司的 50 日移動平均線為 11.85 美元，200 日移動平均線為 11.44 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，HC Wainwright 在 11 月 8 日的研究報告中重申了對 Dynavax Technologies 的 “買入” 評級，並給出了 29.00 美元的目標價。</p>
<p><strong>查看我們對 Dynavax Technologies 的最新股票分析</strong></p>
<h2>Dynavax Technologies 公司簡介</h2>
<p>（免費報告）</p>
<p>Dynavax Technologies Corporation 是一家商業階段的生物製藥公司，專注於在美國開發和商業化疫苗。它在美國和歐洲市場銷售 HEPLISAV-B，這是一種用於預防所有已知亞型的乙型肝炎病毒感染的乙型肝炎疫苗，適用於 18 歲及以上人羣。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Dynavax Technologies</li>
<li>股息捕獲策略：你需要知道的事項</li>
<li>Guidewire Software 提供了期待已久的購買機會</li>
<li>什麼是歐元 STOXX 50 指數？</li>
<li>最近這三項分析師股票升級背後的原因是什麼？</li>
<li>投資石油股票的方式和原因</li>
<li>仍被低估的快速增長公司</li>
</ul>
<p><strong>想看看其他對沖基金持有的 DVAX 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Dynavax Technologies Co.（納斯達克代碼：DVAX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<p>→ 馬斯克的新公司可能超過一萬億？（來自 Paradigm Press）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg"/></p>
<h2>你現在應該投資 1,000 美元在 Dynavax Technologies 嗎？</h2>
<p>在考慮 Dynavax Technologies 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Dynavax Technologies 並不在名單上。</p>
<p>雖然 Dynavax Technologies 目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

德納維制藥

<p>蘇黎世州立銀行在第三季度將其在 Dynavax Technologies Co.（NASDAQ:DVAX）的持股減少了 78.1%，目前持有 25,880 股，出售了 92,157 股。其他機構投資者，包括文藝復興科技和 Great Point Partners，也調整了他們的持倉。Dynavax Technologies 的市值為 16.9 億美元，市盈率為 98.85。分析師維持 “買入” 評級，目標價為 10.00 美元。該公司專注於開發疫苗，包括用於乙型肝炎的 HEPLISAV-B</p>

<p>Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 78.1% in the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 25,880 shares of the biopharmaceutical company's stock after selling 92,157 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Dynavax Technologies were worth $288,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>蘇黎世州立銀行在其最近向證券交易委員會提交的文件中表示，在第三季度將其在 Dynavax Technologies Co.（納斯達克代碼：DVAX - 免費報告）的股份減少了 78.1%。該基金在此期間出售了 92,157 股後，持有 25,880 股該生物製藥公司的股票。根據其最近向證券交易委員會提交的文件，蘇黎世州立銀行在 Dynavax Technologies 的持股價值為 288,000 美元。</p>
</div><p>Get <strong>Dynavax Technologies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Dynavax Technologies</strong> 警報：</p>
</div><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company's stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its position in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Millennium Management LLC purchased a new stake in Dynavax Technologies in the 2nd quarter valued at $17,615,000. Mizuho Markets Americas LLC increased its stake in shares of Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company's stock worth $15,369,000 after acquiring an additional 204,475 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after acquiring an additional 82,449 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也買賣了該股票的股份。Renaissance Technologies LLC 在第二季度將其在 Dynavax Technologies 的股份增加了 2.2%。Renaissance Technologies LLC 現在擁有 2,478,178 股該生物製藥公司的股票，價值 27,830,000 美元，此前在上個季度又購買了 53,600 股。Great Point Partners LLC 在第二季度將其在 Dynavax Technologies 的持倉增加了 87.7%。Great Point Partners LLC 現在擁有 2,374,000 股該生物製藥公司的股票，價值 26,660,000 美元，此前在上個季度又購買了 1,109,080 股。Millennium Management LLC 在第二季度購買了 Dynavax Technologies 的新股份，估值為 17,615,000 美元。Mizuho Markets Americas LLC 在第三季度將其在 Dynavax Technologies 的股份增加了 17.4%。Mizuho Markets Americas LLC 現在擁有 1,379,582 股該生物製藥公司的股票，價值 15,369,000 美元，此前在上個季度又收購了 204,475 股。最後，加拿大蒙特利爾銀行在第三季度將其在 Dynavax Technologies 的持股增加了 8.3%。加拿大蒙特利爾銀行現在擁有 1,077,081 股該生物製藥公司的股票，價值 11,848,000 美元，此前在此期間又收購了 82,449 股。96.96% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Dynavax Technologies Price Performance</h2>
<div class="lb-trans"><h2>Dynavax Technologies 價格表現</h2>
</div><p>Dynavax Technologies stock opened at $12.85 on Monday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The firm has a market cap of $1.69 billion, a PE ratio of 98.85 and a beta of 1.33. The company's 50 day moving average is $11.85 and its two-hundred day moving average is $11.44.</p>
<div class="lb-trans"><p>Dynavax Technologies 的股票在週一開盤價為 12.85 美元。該公司的速動比率為 12.34，流動比率為 13.23，債務與股本比率為 0.33。Dynavax Technologies Co.的 52 周最低價為 9.74 美元，52 周最高價為 15.01 美元。該公司的市值為 16.9 億美元，市盈率為 98.85，貝塔值為 1.33。該公司的 50 日移動平均線為 11.85 美元，200 日移動平均線為 11.44 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, HC Wainwright reissued a &#34;buy&#34; rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 11 月 8 日的研究報告中重申了對 Dynavax Technologies 的 “買入” 評級，並給出了 29.00 美元的目標價。</p>
</div><p><strong>View Our Latest Stock Analysis on Dynavax Technologies</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Dynavax Technologies 的最新股票分析</strong></p>
</div><h2>Dynavax Technologies Company Profile</h2>
<div class="lb-trans"><h2>Dynavax Technologies 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p>
<div class="lb-trans"><p>Dynavax Technologies Corporation 是一家商業階段的生物製藥公司，專注於在美國開發和商業化疫苗。它在美國和歐洲市場銷售 HEPLISAV-B，這是一種用於預防所有已知亞型的乙型肝炎病毒感染的乙型肝炎疫苗，適用於 18 歲及以上人羣。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Dynavax Technologies</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Guidewire Software Provides Long-Awaited Buying Opportunity</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>What’s Behind These 3 Recent Analyst Stock Upgrades?</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Fast-Growing Companies That Are Still Undervalued</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Dynavax Technologies</li>
<li>股息捕獲策略：你需要知道的事項</li>
<li>Guidewire Software 提供了期待已久的購買機會</li>
<li>什麼是歐元 STOXX 50 指數？</li>
<li>最近這三項分析師股票升級背後的原因是什麼？</li>
<li>投資石油股票的方式和原因</li>
<li>仍被低估的快速增長公司</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DVAX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 DVAX 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Dynavax Technologies Co.（納斯達克代碼：DVAX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><p>→ Musk’s new company could top a trillion? (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 馬斯克的新公司可能超過一萬億？（來自 Paradigm Press）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10672&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Dynavax Technologies right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Dynavax Technologies 嗎？</h2>
</div><p>Before you consider Dynavax Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Dynavax Technologies 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Dynavax Technologies 並不在名單上。</p>
</div><p>While Dynavax Technologies currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Dynavax Technologies 目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

蘇黎世州銀行出售德納維製藥公司（NASDAQ:DVAX）的股票